During the corresponding time, Caribou Biosciences Inc saw a revenue deteriorated by -43.79 % year on year, sequentially revenue fell by -37.46 %. While revenue at the Caribou Biosciences Inc 's corporate clients
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 ASCO Annual MeetingCaribou Biosciences, a leading biotechnology company specializing in genome editing and cell therapy, recently presented promising clinical data from their CB-010 ANTLER Phase 1 trial at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data showed that CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, holds the potential to rival the efficacy and safety profile of approved autologous CAR-T cell therapies.One of the key findings from the trial was the significant improvement in median progression-free survival (PFS) among...
CARIBOU BIOSCIENCES PRESENTS GROUNDBREAKING CAS12a chRDNA GENOME EDITING TECHNIQUE FOR IN VIVO GENE DISRUPTION AT ASGCT ANNUAL MEETINGBERKELEY, Calif., April 15, 2024 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has made an exciting breakthrough in the field of genetic medicine. The company announced today that their abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT). This prestigious event is scheduled to take place from May 7-11, 2024, in Baltimore, Mar...
The development of patient-centered therapies for autoimmune disorders is a pressing concern that Caribou Biosciences seems to excel in addressing. In its recent announcement, the FDA has cleared the Investigational New Drug (IND) application for Caribou s CB-010 in lupus nephritis and extrarenal lupus - a monumental step towards establishing a robust treatment plan for these conditions. This decision seeds the commencement of the GALLOP Phase 1 clinical trial, aspiring to commence by the end of 2024.Initial Success in ANTLER Trial: A Springboard for CB-010 s Expansion into Autoimmune DiseasesBuilding on the promising initial safety and efficacy results of the ongoing ANTLER trial for relapsed or refractory ...
: This article discusses the recent appointment of Tim Kelly as the Chief Technology Officer (CTO) of Caribou Biosciences, a leading biotechnology company focused on genome engineering. Additionally, it highlights significant clinical catalysts expected in 2024, including the Phase 1 trial data expansion of CB-010 ANTLER and the company s plans for a Phase 3 pivotal trial in second-line (2L) diffuse large B-cell lymphoma (LBCL).
Caribou Biosciences, a frontrunner in the field of genome engineering, has announced the appointment of Tim Kelly as Chief Technology Officer. This strategic hiring reflects Caribou s commitment...
Sources:
Caribou Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Caribou Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Caribou Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
250.17 %